Accelerate clinical trials with AI screening
In biomarker-driven trials, most molecular tests come back negative. Waiv’s AI reads the H&E slide and flags the patients most likely to qualify, so only they go on to confirmatory testing.
How AI screening works
Every routine H&E slide is scanned
The diagnostic slides you already have. No extra tissue is used.
AI flags high-likelihood patients
Waiv’s model predicts the biomarker from each slide. Only these patients go on to testing.
Confirmatory testing finds the positives
Fewer negative molecular tests, less tissue and budget spent, faster enrollment.
Cut diagnostic testing costs
Our AI screens patients directly from routine H&E slides and identifies those unlikely to carry the biomarker. Confirmatory tests go to the most likely candidates to decide eligibility.
When most tests come back negative, every eligible patient is expensive to find. AI-powered screening focuses confirmatory testing on likely positives, so you spend less to enroll each one.
Fewer unnecessary tests means more lab capacity and more tissue preserved, which is especially valuable in indications where tissue is scarce.
Accelerate patient recruitment
Our AI delivers a clear call on whether confirmatory testing is recommended, a biomarker likelihood score, and the slide areas that drove the prediction. Sites know who to send for confirmatory testing without waiting.
By prioritizing likely-positive patients, screening identifies the patients your trial needs with fewer tests, so enrollment completes sooner.
A Phase 3 trial costs around $55,000 a day to run. Every day of enrollment saved goes straight back to your budget.
Fast-track your drug’s path to market
Faster enrollment shortens the whole trial and brings your launch date forward.
Arriving earlier strengthens your position against competitors in the same indication.
Launching earlier increases the value of your drug’s revenue over its lifetime, even after accounting for patent and exclusivity effects.
From slide to screening result in minutes
Waiv screening fits into the workflow your sites already run. Nothing changes at diagnosis, and only likely-positive patients move on to molecular testing.
The routine H&E slide prepared at diagnosis. No extra tissue or new stain required.
The slide is scanned directly at the pathology lab, or at a central lab.
Our AI biomarker test, powered by robust H&E foundation models, predicts status within minutes.
Likely-positive patients go on to confirmatory testing before trial inclusion.
Fewer negative molecular tests, less tissue and budget spent, and faster enrollment.
Built on clinical-grade AI
We have taken AI pathology tests from development through CE-IVDR certification and into routine clinical use.
Our tests are validated in large, multi-center clinical studies across Europe and the US.
More than 66 publications, built on data from over 80 academic institutions representing more than 600 hospitals and labs.
Results in minutes from the existing H&E slide, with no tissue consumed and consistent results every time.
The AI that screens your trial patients can be developed into a CDx or IVD for use after approval.